🔎︎
A systematic review in the BMJ analyzing discontinuation outcomes for weight-management medications reveals that assumptions about treatment duration in current cost-effectiveness models may underestimate the rate of weight regain. Oxford researchers examined 37 studies involving 9,341 participants and found an average monthly weight regain of 0.4 kilograms after medication cessation, with a projected return to baseline weight within 1.7 years, rather than the three years assumed in some economic models.
The analysis included various weight-management medications, with an average treatment duration of 39 weeks. For newer incretin mimetics, such as semaglutide and tirzepatide, weight regain accelerated to 0.8 kilograms per month, indicating that the baseline will be reached in 1.5 years. Real-world evidence indicates that approximately half of patients discontinue treatment within a year, which is much shorter than the time frames used in clinical trials and cost-effectiveness models.
Cardiometabolic improvements achieved during active treatment reversed rapidly after cessation. Within 1.4 years, hemoglobin A1c, fasting glucose, blood pressure, cholesterol, and triglycerides returned to normal levels. This finding contrasts with behavioral weight management programs, which demonstrated sustained cardiometabolic benefits for approximately five years after program completion despite slower initial weight loss.
The review found that people who stopped taking medication gained weight back 0.3 kilograms per month faster than those who stopped following a behavioral program, regardless of how much weight they had lost at first. Supplemental behavioral support during medication treatment or after cessation failed to slow weight regain rates, suggesting medication-induced weight loss may not develop the behavioral skills that support long-term maintenance.
These findings have direct implications for coverage policy and utilization management. Current National Institute for Health and Care Excellence models for semaglutide and tirzepatide assume weight regain over two to three years, while observed data project more rapid regain. Accurate weight-regain trajectories are essential for formulary decisions and the development of prior authorization criteria, particularly as medication costs remain substantial and discontinuation rates are high. The evidence supports treating these medications as chronic therapies requiring indefinite continuation rather than time-limited interventions, which fundamentally alters utilization projections and budget impact analyses.
